

[View this email in your browser](#)



# REPRIEVE

## Randomized Trial to Prevent Vascular Events in HIV

### Trial Status

January 28th, 2019

**7464** participants are enrolled

**26** participants enrolled in the past week

**109** participants are in screening

**116** sites are open for enrollment

**16** sites enrolled at least 1 participant in the past week

**19** sites screened at least 1 participant in the past week

Thank you for the excellent effort that all teams are putting forth to enroll participants in  
REPRIEVE.

---


## Enrollment is Approaching 7500!!!

The REPRIEVE enrollment thermometer has been taken out of retirement to show you how far we have come and how close we are to our target!

We are so pleased that enrollment is quickly approaching 7500 participants and we appreciate every effort to screen and enroll participants to achieve our target enrollment.

Watch for emails about closure to screening as well as the date of closure to accrual.

*Be aware, enrollment cannot exceed 7575 participants.*



**Thank You to All Sites That Enrolled At Least 1 Participant in the Past Week!**

- UCLA CARE Center CRS
- Cincinnati CRS
- Barranco CRS
- San Miguel CRS
- SOWETO
- Joint Clinical Research Centre (JCRC)/Kampala CRS
- Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS
- Parirenyatwa CRS
- GHESKIO Institute of Infectious Diseases and Reproductive Health
- University of Rochester Adult HIV Therapeutic Network CRS
- Thai Red Cross AIDS Research Center
- Drexel University
- Vancouver ID Research and Care Centre Society
- Toronto General Hospital
- Tufts Medical Center
- Tropical Medicine Foundation



Don't forget, we are in our final push to the finish line! The REPRIEVE Leadership Team wants to recognize the *extra* effort and cost of recruiting these final participants.

We have been keeping track of enrollment since September 10th and will continue until the enrollment of the 7500th participant!

*The top 3 enrolling sites over the course of the challenge, will receive \$1000 USD, \$750 USD, or \$500 USD respectively for the extra effort to enroll.*

*Any site that enrolls more than 5 participants during the course of the campaign will receive 100 USD.*

### ***Check out the current standings below!***

Standing	Site Name and Number	Participants Enrolled Since 9/10/18
1 <sup>st</sup> Place	Parirenyatwa CRS 30313	61
2 <sup>nd</sup> Place	Thai Red Cross AIDS Research Center Site 31802	27
3 <sup>rd</sup> Place	Durban International CRS 11201	25
4 <sup>th</sup> Place	BJMC CRS 31441	24
5 <sup>th</sup> Place	Joint Clinical Research Centre (JCRC)/Kampala CRS 12401	22


***Keep up the great work!!***

## **DSMB Summary Report**

Don't forget to forward the DSMB summary report to your Institutional Review Board (IRB)/Ethics Committee (EC)!

If you missed the email with the DSMB summary, the summary is available on the REPRIEVE (A5332) protocol website under Study Monitoring (NHLBI DSMB Reports).

It is recommended that everyone use discretion in sharing the summary with others, since technical language may be subject to misinterpretation.



**When: Wednesday, March 6th 12:00–1:15 PM**

**Where: Grand Hyatt, 721 Pine St, Seattle, WA**

This meeting will be an excellent opportunity to meet with the REPRIEVE team and to celebrate our recent successes!

If you are planning on attending CROI [click here](#) to register for the Investigator's Meeting by Friday, February 22nd.


## A Note About ECG Machines

Once enrollment is complete the REPRIEVE CCC will be reaching out to sites to return their ECG machine. In anticipation of this [please do the following](#):

1. Make sure your site has transmitted all ECGs to IQVIA.
2. Confirm the original ECG tracings are available in participant files.

### Expectations of sites prior to shipping:

- Sites are expected to pack the ECG machine and accessories in the original box including all accessories (cables and power cord).
- Sites are not expected to return unused electrodes or paper.
- Sites need to return the device to the equipment warehouse as per instructions that will be provided.



The ACTG Leadership and Operations Center (LOC) has moved from Brigham and Women's Hospital (BWH) to University of California, Los Angeles (UCLA) as of December 1st, 2018.

Please know that REPRIEVE operations will remain at Massachusetts General Hospital (MGH), and payments will continue to be made from MGH. Below is a detailed table that both ACTG and REPRIEVE sites can reference for PI and contact information for their respective studies.

	Enrollment Status	Network	PI(s)	Contact Email
REPRIEVE (A5332) (U01HL123336)	Enrolling	ACTG* /REPRIEVE	Steven Grinspoon, MD, Pamela Douglas, MD, Udo Hoffmann, MD, Heather Ribaldo, PhD	<a href="mailto:REPRIEVE.finance@mgh.harvard.edu">REPRIEVE.finance@mgh.harvard.edu</a>
Mechanistic Substudy of REPRIEVE (A5333s) (U01HL123336)	Closed to enrollment	ACTG	Markella Zanni, MD and Sara Looby, PhD	<a href="mailto:REPRIEVE.finance@mgh.harvard.edu">REPRIEVE.finance@mgh.harvard.edu</a>
Women's Ancillary Objective (R01AI123001)	Enrolling	ACTG /REPRIEVE	Kristine Erlandson, MD and Todd Brown, MD	<a href="mailto:REPRIEVE.finance@mgh.harvard.edu">REPRIEVE.finance@mgh.harvard.edu</a>
PREPARE (A5361s) (R01AG054366)	Closed to enrollment	ACTG	Turner Overton, MD	<a href="mailto:Kristine.Erlandson@ucdenver.edu">Kristine.Erlandson@ucdenver.edu</a>
Kidney Ancillary Objective (R01DK108438)	Closed to enrollment	ACTG		<a href="mailto:everton@uabmc.edu">everton@uabmc.edu</a>

\*Only applies to ACTG sites. Supplement # 1 (\$500/per participant enrolled): Sites were previously paid by the BWH LOC through their current existing ACTG PF contracts up until 11/30/18. As of 12/01/18, UCLA will disperse this supplement. Contact Meg Robles at [MMRobles@mednet.ucla.edu](mailto:MMRobles@mednet.ucla.edu) for any payment related questions.



**Save the Date!**  
**Tuesday, February 19th, 2019**  
**1:00 – 2:00 PM ET**

For the February Monthly Site Call!

Watch for the email announcement with more details.

**REPRIEVE (A5332): Are you up to date?**

*For A5332 please use:*

*Protocol Version 4.0 dated 03/28/2018*

*V4.0 LOA #1 dated 05/16/2018*

*MOPS Version 4.0 dated 10/16/18*

*A5332 LPC for ACTG Sites Version 4.0 dated 03/22/2018*

*A5332 LPC for Non-ACTG Sites Version 4.0 dated 07/23/2018*

*These documents are on the [A5332 PSWP](#)*

## ***Mechanistic Substudy of REPRIEVE (A5333s): Are you up to date?***

***For A5333s please use***

*Protocol Version 4.0 dated 03/28/2018*

*MOPS Version 4.0 dated 04/10/2018*

*A5333s LPC Version 4.0 dated 03/23/2018*

*These documents are on the [A5333s PSWP](#)*

**For future reference, all newsletters are available on the [REPRIEVE Website](#).**

*We welcome ideas and suggestions for future newsletters. Please submit any comments or suggestions to the REPRIEVE News team at [reprieve.news@fstrf.org](mailto:reprieve.news@fstrf.org)*



---

### **REPRIEVE Trial Clinical Coordinating Center**

Massachusetts General Hospital  
55 Fruit Street, 5LON 207  
Boston, MA USA 02144

**Our mailing address is:**  
[reprieve.news@fstrf.org](mailto:reprieve.news@fstrf.org)

Want to change how you receive these emails?  
You can [update your preferences](#) or [unsubscribe from this list](#).

---

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)  
Massachusetts General Hospital · 5 Longfellow Place · Boston, MA 02214 · USA

